Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand the step-by-step process of refinancing with a concise overview of what happens at each stage.
15,155 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Bitcoin continues its climb for the month, pressing into a critical resistance zone. Traders await a confirmed breako...
A fresh court filing broadens a veteran-focused mortgage case, accusing Veterans United of bait-and-switch tactics an...
BBB Foods reports Q1 2026 results with modest revenue growth and steadier margins. This review translates the transcr...
XRP trades near $1.42 after a volatile week that left many investors debating whether to cut losses or hold for a reb...
A 25-year-old CEO leads a bold new player into federal banking with an OCC charter and a $40 million funding round, s...
AST SpaceMobile posted disappointing quarterly revenue in after-hours trading, triggering a drop in spacemobile’s sto...
After a Q1 earnings miss, Coinbase investors are eyeing a bold growth thesis centered on subscription revenue, deriva...
Bitcoin surged toward a crucial resistance level as news spread that trump just flew china and a tech-heavy delegatio...
Palantir posted solid Q1 2026 growth, but the stock fell as investors priced in a valuation reset and AI competition....
A new defense startup is challenging traditional missiles with a car-like manufacturing model, backed by a $5 million...
In a chaotic but decisive session, the CLARITY Act survived chaotic senate moves and cleared the Senate Banking Commi...